Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), a pioneering clinical stage biopharmaceutical company dedicated to advancing innovative treatments for brain health disorders, has announced a strategic license agreement with Catalent, a renowned leader in facilitating the development and provision of enhanced treatments for patients worldwide. This collaboration will grant MindMed access to Catalent’s esteemed Zydis® orally disintegrating tablet (ODT) technology.

Within the terms of this licensing agreement, Catalent is providing MindMed with access to its Zydis technology for the advancement of MindMed’s flagship product candidate MM-120 (lysergide D-tartrate). MM-120 represents a proprietary and pharmaceutically optimized form of lysergide. Notably, this agreement also extends exclusive rights to MindMed for leveraging the Zydis technology to develop all salt and polymorphic variants of lysergide in key regions, including the United States, United Kingdom, and the European Union. The Zydis ODT technology offers a unique freeze-dried oral solid dosage form, enabling rapid dissolution in the mouth without the need for water. Renowned for its effectiveness, Zydis stands as one of the most successful ODTs globally, surpassing conventional oral dosage forms in terms of patient adherence, convenience, and compliance.

Robert Barrow, Chief Executive Officer and Director of MindMed, expressed his enthusiasm, stating, “We aim to develop best-in-class brain health treatments that have the potential to reach patients in need and are pleased to be working with Catalent, a global CDMO leader with broad, deep-scale expertise in delivery technologies, and multi-modality manufacturing capabilities to reach this objective.” He further emphasized that the Zydis ODT delivery technology has the potential to enhance the competitiveness of MM-120, optimizing its pharmaceutical product while expanding the company’s intellectual property portfolio.

Tom Hawkeswood, President, Division Head of Pharma Product Delivery at Catalent, emphasized the organization's eagerness to collaborate, stating, “Catalent has a proven track record in working with partners to bring novel therapies through the clinic and to market quickly and we look forward to working with MindMed in the development of this potentially life-changing new product candidate.”

Currently, MindMed is engaged in a Phase 2b trial evaluating MM-120’s efficacy in treating generalized anxiety disorder (GAD), with anticipated topline data expected in the fourth quarter of 2023. This multi-faceted trial assesses various doses of MM-120, and its outcomes hold significant promise for the future of anxiety disorder treatments.

About MindMed

MindMed is a clinical stage biopharmaceutical company dedicated to advancing treatments for brain health disorders. The organization is committed to becoming a global leader in the development and delivery of groundbreaking treatments to enhance patient outcomes. The company's innovative pipeline comprises products targeting neurotransmitter pathways central to brain health disorders. Trading under the symbols MNMD on NASDAQ and MMED on the Canadian NEO Exchange, MindMed is at the forefront of innovative healthcare advancements.

Report Abuse